Comment on CMS-2026-1255-0001
Cholangiocarcinoma FoundationSupportAdvocacy
Summary: The Cholangiocarcinoma Foundation, represented by its Chief Medical Officer, supports the modernization of prior authorization processes but urges CMS to implement specific protections for oncology patients. They argue that rigid prior authorization requirements for laboratory and biomarker testing can cause critical delays in cancer care and request that CMS require health plans to allow retroactive authorization and expedited reviews.
See attached file(s)